* diagnosis of covid-19+ * retinopathies, * hydroxychloroquine or other prophylactic treatments for vidoc19 within one month prior to inclusion and throughout the study. * hypersensitivity to chloroquine or hydroxychloroquine or 4-aminoquinolines or any of the other components of this drug, * contraindication to prophylactic use of chloroquine, e.g. liver failure, known epilepsy, creatinine clearance \< 30 ml/min. * inability to be monitored during the trial period * pregnancy and breastfeeding * psoriasis

* diagnosis of covid-19+ * retinopathies, * hydroxychloroquine or other prophylactic treatments for vidoc19 within one month prior to inclusion and throughout the study. * hypersensitivity to chloroquine or hydroxychloroquine or 4-aminoquinolines or any of the other components of this drug, * contraindication to prophylactic use of chloroquine, e.g. liver failure, known epilepsy, creatinine clearance \< 30 ml/min. * inability to be monitored during the trial period * pregnancy and breastfeeding * psoriasis

- diagnosis of covid-19+ - retinopathies, - hydroxychloroquine or other prophylactic treatments for vidoc19 within one month prior to inclusion and throughout the study. - hypersensitivity to chloroquine or hydroxychloroquine or 4-aminoquinolines or any of the other components of this drug, - contraindication to prophylactic use of chloroquine, e.g. liver failure, known epilepsy, creatinine clearance < 30 ml/min. - inability to be monitored during the trial period - pregnancy and breastfeeding - psoriasis

- diagnosis of covid-19+ - retinopathies, - hydroxychloroquine or other prophylactic treatments for vidoc19 within one month prior to inclusion and throughout the study. - hypersensitivity to chloroquine or hydroxychloroquine or 4-aminoquinolines or any of the other components of this drug, - contraindication to prophylactic use of chloroquine, e.g. liver failure, known epilepsy, creatinine clearance < 30 ml/min. - inability to be monitored during the trial period - pregnancy and breastfeeding - psoriasis